Intravascular Ultrasound

Intravascular ultrasound (IVUS) is an catheter-based imaging technique that uses sound waves to visualize vessel walls and plaque from within an artery. It supports lesion assessment, stent sizing and optimization, and procedural decision-making in coronary and peripheral interventions. Its clinical value is strongest when angiography alone does not adequately characterize vessel dimensions, calcification, remodeling, or treatment results.

The field is moving from angiography-led assessment toward complementary intravascular imaging, particularly for complex lesions, left-main disease, long lesions, bifurcations, heavy calcification, and uncertain vessel sizing. Greater attention to procedural quality, avoidance of stent underexpansion, and documentation of treatment results is reinforcing the role of IVUS. Adoption is also shaped by operator training, workflow integration, reimbursement, evidence requirements, and access to catheterization laboratories.

Artificial intelligence can support IVUS through automated lumen and vessel-wall segmentation, plaque characterization, lesion measurement, stent assessment, and longitudinal comparison. Its practical contribution depends on representative training data, reliable performance across devices and patient populations, transparent validation, and integration with imaging consoles and clinical records. AI should augment-not replace-physician interpretation, with human oversight for artifacts, atypical anatomy, and treatment decisions.

North America emphasizes evidence-based procedural quality, specialized cardiovascular centers, and integration with advanced interventional workflows. Europe combines mature clinical expertise with structured health-technology assessment and varied reimbursement environments. Asia-Pacific shows expanding interventional capacity alongside substantial differences in infrastructure, training, and access. Latin America is influenced by concentration of advanced care in major urban centers and procurement constraints. The Middle East is developing specialized cardiac services, while Africa faces wider limitations in equipment availability, trained personnel, and referral pathways. Across all regions, education, service support, and interoperability are central adoption conditions.

ASEAN markets present diverse healthcare systems and varying levels of catheterization-laboratory capability, making scalable training and distribution models important. BRICS members span advanced and emerging interventional environments, with domestic manufacturing, affordability, and public-sector procurement influencing access. The European Union benefits from cross-border clinical and regulatory coordination, although national reimbursement remains influential. G7 systems generally have strong specialist capacity but face cost, workforce, and evidence pressures. GCC countries are investing in sophisticated cardiovascular services, while NATO members reflect diverse but often well-established clinical networks and procurement frameworks.

Australia and Canada combine specialist expertise with geographically dispersed access challenges. Brazil, Mexico, India, China, and Russia include major tertiary centers alongside substantial regional variation in infrastructure and affordability. France, Germany, Italy, Spain, and the United Kingdom have established interventional cardiology capabilities, with differing reimbursement, procurement, and evidence pathways. Japan and South Korea have advanced hospital systems and strong technical expertise, while the United States remains highly focused on procedural evidence, imaging utilization, and workflow efficiency. Across these countries, local training, regulatory clearance, hospital budgets, and clinical guidelines determine practical uptake.

Leaders should align IVUS deployment with clearly defined clinical pathways, especially complex and high-risk interventions, and measure outcomes such as procedural optimization, repeat intervention, complications, and workflow time. Investments should pair consoles and catheters with structured operator training, proctoring, service coverage, and multidisciplinary governance. Developers and providers should prioritize interoperability, explainable AI, cybersecurity, and validation across anatomies and devices. Regional strategies should reflect reimbursement realities, public-private procurement structures, referral patterns, and the availability of trained imaging specialists.

This executive summary uses a structured synthesis of the intravascular ultrasound domain, focusing on clinical applications, technology development, adoption conditions, regional variation, and healthcare-system factors. Interpretation should be grounded in peer-reviewed clinical literature, professional-society guidance, regulatory documentation, hospital practice evidence, reimbursement policies, and interviews with qualified stakeholders. Findings should be cross-checked across sources, separated into established evidence and emerging signals, and updated as imaging platforms, AI tools, procedural guidelines, and access conditions evolve.

IVUS is increasingly relevant where precise anatomical assessment and optimization can improve the quality of endovascular treatment. Its impact will depend less on equipment availability alone than on clinical selection, operator competence, workflow integration, reimbursement, and credible evidence of value. Organizations that combine imaging expertise with disciplined implementation, interoperable technology, and responsible AI governance will be better positioned to translate IVUS capabilities into consistent patient-care benefits.